Blood pressure and anthropometry in children treated with stimulants: a longitudinal cohort study with an individual approach
Authors Landgren M, Nasic S, Johnson M, Lövoll T, Holmgren D, Fernell E
Received 30 September 2016
Accepted for publication 17 November 2016
Published 16 February 2017 Volume 2017:13 Pages 499—506
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 4
Editor who approved publication: Dr Roger Pinder
Magnus Landgren,1,2 Salmir Nasic,3 Mats Johnson,1,2 Trygve Lövoll,1 Daniel Holmgren,4,5 Elisabeth Fernell2
1Department of Pediatrics, Unit of Developmental Disorders, Skaraborg’s Hospital, Mariestad, 2Gillberg Neuropsychiatry Centre, University of Gothenburg, Gothenburg, 3Research and Development Centre, 4Department of Pediatrics, Skaraborg’s Hospital, Skövde, 5University of Gothenburg, Gothenburg, Sweden
Background: Knowledge about the long-term effects on blood pressure (BP) and body mass index (BMI) when treating young patients for attention-deficit/hyperactivity disorder (AD/HD) with stimulants is limited. Most of the studies have reported mean and not individual values for anthropometrics and BP in treatment with stimulants. This seems to be the first study of changes based on the analyses of individual data measured over time.
Patients and methods: Seventy young patients (aged 8–18 years) diagnosed with AD/HD and responding well to treatment with stimulants were followed for a mean period of 3 years and 3 months. BP, heart rate, height, weight, and BMI were transformed to standard deviations or z-scores from before treatment to the last registered visit.
Results: The mean dose of methylphenidate was 0.95 mg/kg. The mean increase of systolic and diastolic BP was 0.4 z-score and 0.1 z-score, respectively. The systolic BP was associated with BMI; a higher BMI at baseline increased the risk for an increase in systolic BP. Ten percent of the total group had a weight at follow-up of <-1.5 standard deviation (SD) and 12% had a height of <-1.5 SD. Mean height at follow-up was -0.2 SD, but 40% had a reduced height of at least 0.5 SD during the treatment period. BMI on a group level was reduced from +0.8 SD to +0.3 SD. Of the 19 patients with a BMI >+1.5 SD at baseline, 50% had a significantly reduced BMI.
Conclusion: Consequences of stimulant treatment must be evaluated individually. Besides significant effects on core AD/HD symptoms, some patients have lower BMI and BP and some increase/maintain their BMI and/or increase their systolic BP. The risk of reduced height trajectory needs further research.
Keywords: AD/HD, treatment, heart rate, long-term follow-up, methylphenidate, improvement, cardiovascular, overweight, height, BMI, health
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]